AbobotulinumtoxinA: A Review in Pediatric Lower Limb Spasticity

@article{Syed2017AbobotulinumtoxinAAR,
  title={AbobotulinumtoxinA: A Review in Pediatric Lower Limb Spasticity},
  author={Yahiya Y. Syed},
  journal={Pediatric Drugs},
  year={2017},
  volume={19},
  pages={367-373}
}
  • Yahiya Y. Syed
  • Published 2017
  • Medicine
  • Pediatric Drugs
  • AbobotulinumtoxinA (Dysport®) is currently the only botulinum toxin A formulation approved by the US FDA for the treatment of lower limb spasticity in pediatric patients aged ≥2 years. Intramuscular abobotulinumtoxinA was approved based on the results of a pivotal phase 3 trial in children with lower limb spasticity due to cerebral palsy. In this trial, a single treatment cycle with abobotulinumtoxinA 10–15 U/kg/leg injected into the gastrocnemius and soleus muscles significantly improved ankle… CONTINUE READING
    2 Citations

    References

    SHOWING 1-10 OF 27 REFERENCES
    Estimation of botulinum toxin type A efficacy on spasticity and functional outcome in children with spastic cerebral palsy.
    • 14
    • PDF
    Botulinum Toxin A (Dysport®)
    • 9